




FIG.1

cNK: Conventional NK cells
CIML NK: Cytokine-induced memory-like NK cells




FIG.2A




FIG.2B




FIG.2C




FIG.3A





FIG.3B



CAR targeting a neopeptide derived from NPM1c protein

FIG.4




FIG.5




FIG. 6A





FIG. 6B






FIG. 6F





FIG. 7A






FIG.7C




FIG.7D cont. on sheet 13/51

FIG.7D

FIG.7D on sheet 12/51





FIG.7D cont.






FIG.8A




FIG.8B




FIG.8C




FIG. 8D




FIG.8E




FIG.8G





FIG.8F






FIG.9B




FIG.9C




FIG.10A





FIG.10B




FIG.10C




FIG.10D




FIG.10E





FIG.10F




FIG.10G




FIG.11A




FIG.11B




FIG.11C




FIG. 12




FIG.13




FIG.14




FIG.15




FIG.16




FIG.17





FIG.18






FIG. 18 cont.




FIG.18 cont.


UPN	Dose Level	Gender	Age (years)	WHO Dx	BM Blast (%)	KIR Ligand Mismatch	MRG Response	DLT	GVHD
001	1	M	73	M2	16	Yes	TF-PD	No	No
006	1	M	70	M0	28	Yes	TF-PD	No	No
007	1	M	77	M0	47	Yes	CR	No	No
008	2	M	76	t-AML	17	Yes	TF-PD	No	No
009	2	F	73	M1	80	No	MLFS	No	No
012	2	F	71	M5	15	Yes	CR	No	No
017	3	M	64	t-AML	69	Yes	TF-PD	No	No
019	3	F	71	M5	15	Yes	CR	No	No
020	3	M	60	MDS-AML	13	Yes	CRp	No	No
023	3	M	83	M1	86	No	CRp	No	No
025	3	M	72	t-AML	1	No	CR	No	No
027	3	M	76	M1	In CR	No	CRp	No	No
028	3	F	69	HMA failed MDS	6	No	Marrow CR	No	No

>50% CR Rat

2 Long term survivors

1 Died in CR

FIG.19



First 4 patients cleared disease, 2nd patient (TP53 mutated) MRD— by flow & RHP

Massive expansion & prolonged persistence

— Patient # 001
- - - Patient # 002




FIG.21




FIG. 22





FIG.23

Anti-CTLA-4 antibody leads to Treg depletion to facilitate NK cell activity
NK cell infiltration associated with favorable outcomes in H&N ca patients
N-803 is an IL-15 super-agonist which enhances NK cell activation in vivo



First patient treated on 9/15 (platinum/cetux/pembro failure)

>2500 mature NK cells/uL on day 21

IL-15 injection site rash





FIG.24





FIG.25



Schema




FIG.26

NK cell CARs are safe (no CRS/no neurotoxicity), response rate similar to CAR T cells

Limited efficacy of CAR T cells in AML/MDS

Dual targeting of myeloid blasts by Mem-NK cells armed with CARs(*antigen expression triggers CAR vs HLA loss triggers direct NK cell cytotoxicity*)

Primary Peripheral blood NK cells are resistant to transduction




FIG.27




FIG. 28